Pharmaceutical sponsor
Guangzhou Lupeng Pharmaceutical Company LTD. Clinical Trials
Studies where Guangzhou Lupeng Pharmaceutical Company LTD. is the lead sponsor: its pipeline by phase, what is enrolling now and where. Studies it supports as a collaborator are in the search.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 9B-cell Lymphoma
A Study of LP-168 in Participants With Relapse or Refractory B-Cell Lymphoma
This is an open-label, multi-center Phase 1/2 study of oral LP-168 in patients with CLL/SLL and NHL who have failed or are intolerant to standard of care.
- Trial name
- NCT04993690
- Testing
- LP-168 tablet
- Where
- 3 sites in China
- Volunteers
- 200 people
- Sponsor
- Guangzhou Lupeng Pharmaceutical Company LTD.
Acute Myeloid Leukemia, Myelodysplastic Syndromes
A Study to Assess Safety and Preliminary Efficacy of LP-108 Combined With Azacitidine In Subjects With AML, MDS, CMML
This is a Phase 1, open-label, multicenter, dose-escalation \& expansion study to evaluate the safety,tolerability and pharmacokinetics (PK) of LP-108, a BCL-2 inhibitor, combined with azacitidine, to determine the dose limiting…
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia
- Trial name
- NCT05641259
- Testing
- LP-108, Azacitidine
- Where
- 3 sites in China
- Volunteers
- 198 people
- Sponsor
- Guangzhou Lupeng Pharmaceutical Company LTD.
DLBCL
A Study of Rocbrutinib Combined With R-GemOx in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
This is a multicenter, open-label phase Ib study, evaluating the safety, tolerability, preliminary efficacy and PK characteristics of Rocbrutinib (LP-168) combined with R-GemOx in patients with R/R non-GCB DLBCL.
- Trial name
- NCT07570017
- Testing
- Rocbrutinib, R-GemOx
- Where
- 2 sites in China
- Volunteers
- 42 people
- Sponsor
- Guangzhou Lupeng Pharmaceutical Company LTD.
Relapsing-remitting Multiple Sclerosis (RRMS)
A Study of Rocbrutinib in PRL-Positive Relapsing-Remitting Multiple Sclerosis
This is a randomized, controlled, multicenter, open-label Phase IIa clinical study to evaluate the efficacy and safety of rocbrutinib (LP-168), an oral BTK inhibitor, in subjects with paramagnetic rim lesion (PRL)-positive…
- Trial name
- NCT07776743
- Testing
- Rocbrutinib, Dimethyl Fumarate
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Guangzhou Lupeng Pharmaceutical Company LTD.
Mantle Cell Lymphoma (MCL), Diffuse Large B-Cell Lymphoma (DLBCL)
A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies
BTK inhibitors and BCL-2 inhibitors have demonstrated significant clinical activity in mature B-cell malignancies, and combination therapy may provide improved clinical benefit.
- Conditions
- Mantle Cell Lymphoma (MCL), Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma ( FL), Waldenström Macroglobulinemia (WM)
- Trial name
- NCT07609862
- Testing
- Lacutoclax+Rocbrutinib
- Where
- China
- Volunteers
- 92 people
- Sponsor
- Guangzhou Lupeng Pharmaceutical Company LTD.
Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
A Study of Lacutoclax (LP-108) in Patients With Relapsed/Refractory CLL/SLL
The goal of this clinical trial is to evaluate the efficacy and safety of Lacutoclax, an oral selective BCL-2 inhibitor, in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
- Trial name
- NCT07609823
- Testing
- Lacutoclax
- Where
- China
- Volunteers
- 75 people
- Sponsor
- Guangzhou Lupeng Pharmaceutical Company LTD.
Clinical Pharmacology
A Study Evaluating the Effects of Itraconazole or Rifampin on the Pharmacokinetic Characteristics of Rocbrutinib Tablet
This is a phase I, open-label, two-part, fixed-sequence drug interaction study conducted to evaluate the effects of concomitant use of the potent CYP3A4 inhibitor itraconazole or the CYP3A4 inducer rifampin on the…
- Trial name
- NCT07374224
- Testing
- Rocbrutinib tablets, Itraconazole capsules, Rifampicin capsules
- Where
- China
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Guangzhou Lupeng Pharmaceutical Company LTD.
Mantle Cell Lymphoma
A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma
Mantle cell lymphoma (MCL) is an aggressive yet often indolent type of B-cell non-Hodgkin lymphoma (NHL). Rocbrutinib (LP-168) is a novel, highly selective, fourth-generation Bruton's tyrosine kinase (BTK) inhibitor that exhibits…
- Trial name
- NCT07377578
- Testing
- Rocbrutinib, Ibrutinib, Acalabrutinib
- Where
- 2 sites in China
- Volunteers
- 394 people
- Sponsor
- Guangzhou Lupeng Pharmaceutical Company LTD.
Diffuse Large B-Cell Lymphoma (DLBCL)
A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma
This is an open-label, randomized controlled, multicenter Phase II clinical study primarily evaluating the efficacy and safety of Rocbrutinib monotherapy compared to the investigator's choice of BR/R2 regimen in patients with…
- Trial name
- NCT07189065
- Testing
- Rocbrutinib, Bendamustine, Rituximab
- Where
- 41 sites in China
- Volunteers
- 150 people
- Sponsor
- Guangzhou Lupeng Pharmaceutical Company LTD.